Mikkel Wandahl Pedersen

Mikkel Wandahl Pedersen

Auto-generated profile, based on publicly available information

Mikkel Wandahl Pedersen

Symphogen A/S, Ballerup, Denmark

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 August 2013 in Nature Reviews Cancer
Verified
Journal Article
Closed access
NTNiall Tebbutt
Niall Tebbutt
MPMikkel W. Pedersen
Mikkel W. Pedersen
TJTerrance Johns
Terrance Johns

13 January 2010 in Cancer Research
Verified
Journal Article
Closed access
PDF file
MPMikkel Wandahl Pedersen
Mikkel Wandahl Pedersen
HJHelle Jane Jacobsen
Helle Jane Jacobsen
KKKlaus Koefoed
Klaus Koefoed
AHAdam Hey
Adam Hey
CPCharles Pyke
Charles Pyke
MKMichael Kragh
Michael Kragh
Sphingosine-1-phosphate (S1P) has been implicated in tumor angiogenesis by acting through the Gi-coupled chemotactic receptor S1P1. Here, we report that the distinct receptor S1P2 is responsible for mediating the G12/13/Rho-dependent inhibitory effects of S1P on Akt, Rac, and cell migration, thereby negatively regulating tumor angiogenesis and tumor growth. By using S1P2LacZ/+ mice, we found that S1P2 was expressed in both tumor and normal blood vessels in many organs, in both endothelial cells (EC) and vascular smooth muscle cells, as well as in tumor-associated, CD11b-positive bone marrow–derived cells (BMDC). Lewis lung carcinoma or B16 melanoma cells implanted in S1P2-deficient (S1P2−/−) mice displayed accelerated tumor growth and angiogenesis with enhanced association of vascular smooth muscle cells and pericytes. S1P2−/− ECs exhibited enhanced Rac activity, Akt phosphorylation, cell migration, proliferation, and tube formation in vitro. Coinjection of S1P2−/− ECs and tumor cells into wild-type mice also produced a relative enhancement of tumor growth and angiogenesis in vivo. S1P2−/− mice were also more efficient at recruiting CD11b-positive BMDCs into tumors compared with wild-type siblings. Bone marrow chimera experiments revealed that S1P2 acted in BMDCs to promote tumor growth and angiogenesis. Our results indicate that, in contrast to endothelial S1P1, which stimulates tumor angiogenesis, S1P2 on ECs and BMDCs mediates a potent inhibition of tumor angiogenesis, suggesting a novel therapeutic tactic for anticancer treatment. Cancer Res; 70(2); 772–81

1 November 2011 in mAbs
Verified
Journal Article
Open access
KKKlaus Koefoed
Klaus Koefoed
LSLucilla Steinaa
Lucilla Steinaa
JSJosefine Nielsen Søderberg
Josefine Nielsen Søderberg
IKIda Kjær
Ida Kjær
HJHelle Jane Jacobsen
Helle Jane Jacobsen
MPMikkel Wandahl Pedersen
Mikkel Wandahl Pedersen
The epidermal growth factor receptor (EGFR) is frequently dysregulated in human malignancies and a validated target for cancer therapy. Two monoclonal anti-EGFR antibodies (cetuximab and panitumuma...

1 March 2007 in Molecular Cancer Research
Verified
Journal Article
Closed access
ALAlice Bjerregaard Larsen
Alice Bjerregaard Larsen
MPMikkel Wandahl Pedersen
Mikkel Wandahl Pedersen
MSMarie-ThérÉsE Stockhausen
Marie-ThérÉsE Stockhausen
MGMichael Vibo Grandal
Michael Vibo Grandal
BDBo van Deurs
Bo van Deurs
HPHans Skovgaard Poulsen
Hans Skovgaard Poulsen
EphA2 overexpression has been reported in many cancers and is believed to play an important role in tumor metastasis and angiogenesis. We show that the activated epidermal growth factor receptor (EGFR) and the cancer-specific constitutively active EGFR type III deletion mutant (EGFRvIII) induce the expression of EphA2 in mammalian cell lines, including the human cancer cell lines A431 and HN5. The regulation is partially dependent on downstream activation of mitogen-activated protein kinase/extracellular signal–regulated kinase kinase and is a direct effect on the EphA2 promoter. Furthermore, EGFR and EphA2 both localize to the plasma membrane and EphA2 coimmunoprecipitates with activated EGFR and EGFRvIII. Ligand activation of EphA2 and EphA2 knockdown by small interfering RNA inhibit EGF-induced cell motility of EGFR-overexpressing human cancer cells, indicating a functional role of EphA2 in EGFR-expressing cancer cells. (Mol Cancer Res 2007;5(3):283–93)

19 March 2007 in Carcinogenesis
Verified
Journal Article
Open access
PDF file
MGMichael V. Grandal
Michael V. Grandal
RZRoza Zandi
Roza Zandi
MPMikkel W. Pedersen
Mikkel W. Pedersen
BWBerthe M. Willumsen
Berthe M. Willumsen
BDBo van Deurs
Bo van Deurs
HPHans S. Poulsen
Hans S. Poulsen
EGFRvIII is a mutant variant of the epidermal growth factor receptor (EGFR) found exclusively in various cancer types. EGFRvIII lacks a large part of the extracellular domain and is unable to bind ligands; however, the receptor is constitutively phosphorylated and able to activate downstream signaling pathways. Failure to attenuate signaling by receptor down-regulation could be one of the major mechanisms by which EGFRvIII becomes oncogenic. Using a cell system expressing either EGFR or EGFRvIII with no expression of other EGFR family members and with endogenous levels of key degradation proteins, we have investigated the down-regulation of EGFRvIII and compared it to that of EGFR. We show that, in contrast to EGFR, EGFRvIII is inefficiently degraded. EGFRvIII is internalized, but the internalization rate of the mutated receptor is significantly less than that of unstimulated EGFR. Moreover, internalized EGFRvIII is recycled rather than delivered to lysosomes. EGFRvIII binds the ubiquitin ligase c-Cbl via Grb2, whereas binding via phosphorylated tyrosine residue 1045 seems to be limited. Despite c-Cbl binding, the receptor fails to become effectively ubiquitinylated. Thus, our results suggest that the long lifetime of EGFRvIII is caused by inefficient internalization and impaired sorting to lysosomes due to lack of effective ubiquitinylation.

14 September 2015 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
HJHelle J. Jacobsen
Helle J. Jacobsen
TPThomas T. Poulsen
Thomas T. Poulsen
ADAnna Dahlman
Anna Dahlman
IKIda Kjær
Ida Kjær
KKKlaus Koefoed
Klaus Koefoed
JLJohan Lantto
Johan Lantto
Purpose: Accumulating evidence indicates a high degree of plasticity and compensatory signaling within the human epidermal growth factor receptor (HER) family, leading to resistance upon therapeutic intervention with HER family members. Experimental Design/Results: We have generated Pan-HER, a mixture of six antibodies targeting each of the HER family members EGFR, HER2, and HER3 with synergistic pairs of antibodies, which simultaneously remove all three targets, thereby preventing compensatory tumor promoting mechanisms within the HER family. Pan-HER induces potent growth inhibition in a range of cancer cell lines and xenograft models, including cell lines with acquired resistance to therapeutic antibodies. Pan-HER is also highly efficacious in the presence of HER family ligands, indicating that it is capable of overcoming acquired resistance due to increased ligand production. All three target specificities contribute to the enhanced efficacy, demonstrating a distinct benefit of combined HER family targeting when compared with single-receptor targeting. Conclusions: Our data show that simultaneous targeting of three receptors provides broader efficacy than targeting a single receptor or any combination of two receptors in the HER family, especially in the presence of HER family ligands. Pan-HER represents a novel strategy to deal with primary and acquired resistance due to tumor heterogeneity and plasticity in terms of HER family dependency and as such may be a viable alternative in the clinic. Clin Cancer Res; 21(18); 4110–22. ©2015 AACR. See related commentary by Yarden and Sela, p. 4030